Also known as: GVS-111, Omberacetam, N-Phenylacetyl-L-prolylglycine ethyl ester
Noopept is a synthetic peptide-derived nootropic developed in Russia that is estimated to be up to 1.000 times more potent than piracetam on a per-milligram basis. It modulates AMPA and NMDA receptors and increases BDNF and NGF expression.
Noopept (GVS-111, omberacetam) is a dipeptide nootropic developed at the Russian Academy of Medical Sciences in the 1990s. While structurally related to the racetam family, it is technically a peptide-derived compound with a distinct mechanism of action. Noopept is rapidly metabolized into cycloprolylglycine, an endogenous neuropeptide, and modulates both AMPA and NMDA glutamate receptors. Notably, it increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), promoting neuroplasticity and neuroprotection. Clinical trials in Russia have demonstrated improvements in cognitive function and emotional state in patients with mild cognitive disorders of vascular or traumatic origin. Noopept is prescribed as a medication in Russia and several CIS countries but is available as a supplement in the US. It is not approved as a pharmaceutical in the EU, and its legal status varies by country.
Noopept facilitates all stages of memory processing – encoding, consolidation, and retrieval – through AMPA/NMDA receptor modulation and increased BDNF expression in the hippocampus.
Animal and in vitro studies show Noopept increases BDNF and NGF levels in the hippocampus and cortex, supporting synaptic plasticity and neuronal survival.
Divided into 2–3 doses, morning through early afternoon
Much lower dosing than piracetam due to its high potency. Do not exceed 30 mg/day. Cycle recommended: 1.5–3 months on, 1 month off.
Fastest absorption and highest bioavailability
Convenience and standardized dosing
No product recommendations yet.
No reviews yet. Be the first to share your experience!